MEI Pharma, Inc. (MEIP)
NASDAQ: MEIP · Real-Time Price · USD
2.120
-0.035 (-1.62%)
Apr 25, 2025, 12:30 PM EDT - Market open
MEI Pharma Revenue
In the fiscal year ending June 30, 2024, MEI Pharma had annual revenue of $65.30M with 33.76% growth.
Revenue (ttm)
$65.30M
Revenue Growth
+33.76%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
28
Market Cap
14.13M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 65.30M | 16.48M | 33.76% |
| Jun 30, 2023 | 48.82M | 8.12M | 19.95% |
| Jun 30, 2022 | 40.70M | 5.90M | 16.96% |
| Jun 30, 2021 | 34.80M | 7.04M | 25.36% |
| Jun 30, 2020 | 27.76M | 22.84M | 464.72% |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
| Jun 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
MEIP News
- 2 months ago - MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position - Business Wire
- 5 months ago - MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position - Business Wire
- 7 months ago - MEI Pharma Reports Fiscal Year End 2024 Cash Position - Business Wire
- 9 months ago - MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives - Business Wire
- 9 months ago - MEI Pharma to Consider Strategic Alternatives - Business Wire
- 1 year ago - Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP) - Business Wire
- 1 year ago - MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights - Business Wire
- 1 year ago - MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344 - Business Wire